FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: THLD

Sort
E.g., 2013-06-19
E.g., 2013-06-19
Enter a comma separated list of user names.

Threshold Pharmaceuticals, Inc (NASDAQ:THLD) has a license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals. Threshold Pharmaceuticals was founded in 2001 and is headquartered in Redwood City, California.

Tags:

Stock-PR Reporting

FREE Daily Stock Alerts From Stock-PR.com

Tags:

Threshold Pharmaceuticals, Inc (NASDAQ:THLD), a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. The products from Threshold Pharmaceuticals include TH-302, a novel drug candidate which is in Phase 1, Phase 1/2, and Phase 2 clinical trials for cancer.

Tags:

The products from Threshold Pharmaceuticals, Inc (NASDAQ:THLD) include TH-302, a novel drug candidate which is in Phase 1, Phase 1/2, and Phase 2 clinical trials for cancer. Threshold Pharmaceuticals, a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer.

Tags:

Pages

ADVERTISE WITH US